Last $2.40 USD
Change Today -0.15 / -5.88%
Volume 1.1M
BOTA On Other Exchanges
As of 8:10 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

biota pharmaceuticals inc (BOTA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $7.07
52 Week Low
09/17/14 - $2.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

biota pharmaceuticals inc (BOTA) Related Businessweek News

No Related Businessweek News Found

biota pharmaceuticals inc (BOTA) Details

Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing oral, small molecule compounds to treat various respiratory-related viral infections. Its advanced clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor for the treatment of influenza A and B. The company also develops vapendavir, which completed Phase II trials for the treatment of human rhinovirus infections in patients with moderate to severe asthma, as well as completed additional Phase 1 bioavailability and drug-drug interaction studies. In addition, it develops orally bioavailable F and non-F protein compounds for the treatment of respiratory syncytial virus infections in children, the elderly, and immune-compromised patients. Biota Pharmaceuticals, Inc. is headquartered in Alpharetta, Georgia.

66 Employees
Last Reported Date: 09/30/14

biota pharmaceuticals inc (BOTA) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $408.0K
Executive Chairman
Total Annual Compensation: $525.0K
Compensation as of Fiscal Year 2014.

biota pharmaceuticals inc (BOTA) Key Developments

Biota Pharmaceuticals, Inc. Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial

Biota Pharmaceuticals, Inc. announced that it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir. The goal of the study is to enroll approximately 150 laboratory-confirmed human rhinovirus (HRV) infected patients with moderate-to-severe asthma from the United States and multiple European countries over the next 12 months and to report top-line data in mid-2016. The primary endpoint of this multi-center, randomized, double-blind, placebo-controlled dose-ranging study is the change from baseline to study day 14 measured by an asthma control questionnaire (ACQ)-6 total score. The secondary endpoints are focused on safety and tolerability, lung function assessments such as forced expiratory volume in one second, incidence of asthma exacerbations, assessments of the severity and duration of cold symptoms measured by the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) and virological assessments such as changes in viral load.

Anaconda Pharma SAS, Biota Pharmaceuticals, Inc. - M&A Call

To discuss agreement to acquire Anaconda Pharma

Biota Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Month Periods Ended December 31, 2014

Biota Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six month periods ended December 31, 2014. For the quarter, the company reported total revenue of $13.9 million against $18.5 million a year ago. Profit from operations was $6.4 million against loss of $0.1 million a year ago. Profit before tax was $6.5 million against loss before tax of $0.1 million a year ago. Net profit was $6.5 million or $0.19 per diluted share against net loss of $0.1 million or $0.00 per diluted share a year ago. The $6.6 million change in net income from the prior fiscal year period was primarily due to a $9.8 million decrease in the cost of revenue, a $1.4 million increase in foreign exchange gain, a $0.5 million decrease in general and administrative expense and a $0.1 million increase in interest income, offset in part by a $4.6 million decrease in revenue and a $0.6 million increase in research and development expense. Revenue decreased due to a $5.0 million decrease in revenue from services related to the termination of the Company's contract with BARDA on May 7, 2014 and a $0.1 million decrease in other revenue due to a reduced level of grant-related research activities, offset in part by a $0.5 million increase in royalty revenues primarily related to an increase in seasonal sales of Relenza® and Inavir®. For the six months, the company reported total revenue of $14.6 million against $30.8 million a year ago. Loss from operations was $0.6 million against $4.2 million a year ago. Loss before tax was $0.4 million against $4.1 million a year ago. Net loss was $0.4 million or $0.01 per diluted share against $4.0 million $0.14 per diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOTA:US $2.40 USD -0.15

BOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Roche Holding AG SFr.256.10 CHF -4.10
View Industry Companies

Industry Analysis


Industry Average

Valuation BOTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at